Core Viewpoint - NextCure, Inc. and Simcere Zaiming have formed a strategic partnership to develop SIM0505, a novel antibody-drug conjugate targeting CDH6 for solid tumors, with clinical testing expected to begin in the U.S. in Q3 2025 [1][3]. Group 1: Partnership Details - The partnership allows NextCure to access Simcere Zaiming's proprietary linker and TOPOi payload for a preclinical-stage ADC developed by NextCure, while Simcere Zaiming retains Greater China rights to this ADC [4][7]. - Simcere Zaiming is eligible for payments up to $745 million throughout the development phases, including upfront payments and tiered royalties on net sales outside Greater China [5][7]. Group 2: Product Development - SIM0505 is currently undergoing Phase 1 dose escalation studies in China, with a global dose expansion study planned to include multiple tumor types [3][7]. - Preclinical studies of SIM0505 have shown robust anti-tumor activity and a promising safety profile [2][5]. Group 3: Company Background - NextCure is focused on developing innovative therapies for cancer patients who do not respond to existing treatments, utilizing differentiated mechanisms such as antibody-drug conjugates [6]. - Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, aims to develop groundbreaking therapies for cancer patients globally, leveraging its R&D and commercialization capabilities [8].